PapersPMID:30835327
Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.
What moved
1 findingHow to read these marks →- Decreases all-cause mortality
moderate
“All-cause mortality was lower in the CoQ10 group, 10 (9%) patients vs. 24 (20%) patients in the placebo group, corresponding to a relative reduction of 53% (p = 0.040).”
- Study
- RCT
- Dose studied
- CoQ10 (Ubiquinone) 300 mg/day added to standard heart failure therapy
- Population
- European sub-population (n=231) of the Q-SYMBIO trial, moderate-to-severe chronic heart failure, on standard HF therapy in both arms, long-term (2-year) follow-up
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- European sub-population of Q-SYMBIO with moderate to severe heart failure
- Participants
- 231
- Comparator
- placebo
- Duration
- 731 days
- Endpoints measured
- 39